Skip to main content
OpenTrials
Completed

NCT Number: NCT06930235

Effectiveness of Midodrine as an Adjuvant to Norepinephrine in Weaning Critically Ill Patients From Vasopressors

This study aims to evaluate the effectiveness of midodrine as an adjuvant to norepinephrine in weaning critically ill patients from vasopressors

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Shock Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sohag University Hospital

Sohag, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with refractory hypotension on an intravenous vasopressor for more than 24 h but deemed clinically stable.
  • Patients on noradrenaline support <10 μg/min

Exclusion criteria

  • Known allergy to midodrine.
  • Severe shock state, as evidenced by multiple vasopressor infusions or high vasopressor requirement (i.e. noradrenaline >10 μg/min)
  • Patients with severe organic heart disease (e.g., heart failure, sever aortic stenosis), pregnancy, thyrotoxicosis or pheochromocytoma.
  • Those with no enteral route available.

Treatment and study plan

Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine

Drug
  • Patients in group I will receive midodrine (10 mg orally every 8 hours) in addition to administered concurrently with ongoing intravenous norepinephrine after being on norepinephrine for more than 24 hrs.

Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant

Drug

Patients in group II with ongoing intravenous norepinephrine only

Primary outcomes

  1. follow up of critically ill patients on vasopressors

    Time frame: 48 hours

    time of weaning from intravenous vasopressor (norepinephrine)

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 16, 2025
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.